AI Insider·
Insider Brief Artificial intelligence is moving from laboratory experiments into the core infrastructure of drug discovery, healthcare delivery and preventive medicine, according to a new global study from Deep Knowledge Group that argues the next competitive divide will not be who develops AI models, but who can deploy them safely and at scale in life […]
Read full articleArtificial intelligence is restructuring medicine from the exam room to the lab bench. The companies doing it most consequentially are not just digitizing old workflows — they are replacing the underlying logic of how care gets documented, how drugs get discovered, how patients move through the system, and how clinicians access knowledge. From cardiothoracic imaging to whole-brain […]
Biohub's AI toolkit democratizes drug discovery, enabling smaller biotech firms to innovate and compete, potentially transforming the industry. The post Biohub unveils AI world model for protein biology, aiming to reshape drug discovery appeared first on Crypto Briefing.
Bristol Myers' AI integration could revolutionize pharmaceutical processes, enhancing efficiency and safety while setting new industry standards. The post Bristol Myers deploys Anthropic’s Claude AI to accelerate drug discovery appeared first on Crypto Briefing.
SandboxAQ, the Alphabet spinout chaired by former Google CEO Eric Schmidt, has partnered with Anthropic to embed its large quantitative models directly into Claude, making powerful drug discovery and materials science tools accessible through a natural language interface for the first time. The company’s proprietary LQMs are physics-grounded AI models trained on real-world lab data […]
Quantitative models in drug discovery, materials discovery, science and other sectors will now have much wider distribution via Claude PALO ALTO, Calif., May 18, 2026 — SandboxAQ today announced the […] The post SandboxAQ Integrates Its Quantitative AI Models with Anthropic’s Claude via MCP appeared first on AIwire.
Isomorphic Labs raised $2.1B in Series B funding to scale its AI drug design engine, IsoDDE, and move drug candidates into clinical trials.
The LinkedIn cofounder now has an AI drug discovery startup—and thinks not asking chatbots for medical advice is “bordering on committing malpractice.”
Artificial intelligence is fundamentally rewiring how medicines are discovered, designed, and brought to market. The CEOs leading this transformation are compressing timelines that once took a decade into years, and in some cases, months. From generative protein design to AI-optimized clinical trials, these leaders are building the platforms that the world’s largest pharmaceutical companies now […]
